Actemra®

ACTEMRA® (tocilizumab) is a medicine used to treat several inflammatory conditions, including rheumatoid arthritis and other autoimmune diseases. It works by blocking IL-6, a substance in the body that causes inflammation and joint damage.

ACTEMRA® is given by intravenous infusion in hospitals or clinics and is available in two vial sizes:

• 200 mg/10 ml
• 400 mg/20 ml
• 162 mg/0.9 ml

With flexible dosing, it helps reduce pain, swelling, and stiffness, while improving mobility and protecting joints over the long term

Key features

• Active substance: Tocilizumab, a monoclonal antibody targeting IL-6 receptors
• Provides systemic anti-inflammatory action
• Intravenous infusion, hospital or clinical use only
• Dosage flexibility: 200 mg/10 ml and 400 mg/20 ml presentations

Benefits

• Effective in rheumatoid arthritis, systemic juvenile idiopathic arthritis (sJIA), polyarticular JIA, giant cell arteritis (GCA), and cytokine release syndrome (CRS)
• Reduces pain, stiffness, and swelling
• Helps prevent long-term structural damage
• Supports improved mobility and quality of life

Ingredients

• Active ingredient: Tocilizumab (200 mg or 400 mg, depending on vial)
• Excipients: Sucrose, polysorbate 80, arginine hydrochloride, histidine, histidine monohydrochloride monohydrate, water for injections

Package contents

• 1 Vial of 200 mg/10 ml solution for infusion
• 1 Vial of 400 mg/20 ml solution for infusion
• 1 Vial of 162 mg/0.9 mL solution for infusion